scholarly journals Renoprotective opportunities of Lespedeza capitata in patients with chronic kidney disease and type 2 diabetes mellitus

KIDNEYS ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 162-168
Author(s):  
S.V. Kushnirenko ◽  
D.D. Ivanov ◽  
S.A. Rotova ◽  
О.V. Kushnirenko
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Antihypertensive Therapy ◽  
Glucose Lowering ◽  
Type 2 Dm ◽  
Group I ◽  
Ckd Stage ◽  
Lespedeza Capitata ◽  
Group Ii

Background. Today, issues of renoprotection have gone beyond the use of antihypertensive therapy alone. Stable glucose-lowering and urate-lowering therapy are integral parts of modern renoprotection, which improve the functional state of the kidneys by increasing the glomerular filtration rate (GFR) and reducing the albumin excretion rate (AER) and the albumin-to-creatinine ratio (ACR). Nevertheless, hypoazotemic therapy aimed at reducing the content of nitrogenous wastes remains the leading component of the treatment of patients with chronic kidney disease (CKD). The aim of the study is the assessment of the renoprotective potential of the drug Libera (Lespedeza capitata) in patients with CKD stages 2–3 on the background of type 2 diabetes mellitus (DM). Materials and methods. The study included 107 patients with type 2 DM, aged 19 to 75 years (female — 41.1 %, male — 58.9 %), CKD stages 2–3, micro- and macroalbuminuria (category A2 and A3). The patients were divided into two groups: group I — traditional stable glucose-lowering and antihypertensive therapy (n = 50) and group II — traditional stable glucose-lowering and antihypertensive therapy in combination with Libera (Lespedeza capitata) (n = 57), which was prescribed 1 capsule t.i.d. regardless of food intake for 3 months. The criteria for the effectiveness of treatment were dynamics of GFR, AER/ACR in daily urine. The observation period for the patients was 3 months. Results. The renoprotective potential of Lespedeza capitata (Libera) was demonstrated after 3 months of treatment in the form of a significant increase in GFR in patients with CKD stage 2 in group II up to 79.0 ± 1.4 ml/min/1.73 m2 in comparison with the initial data (p < 0.01) and the results obtained in group I after 3 months of using only traditional stable glucose-lowering and antihypertensive therapy (p < 0.05). The use of Libera in the complex treatment of patients of the II group with CKD stage 3 against the background of type 2 DM for 3 months had a positive effect on nitrogen and water excretory kidney function, which manifested itself in an improvement in GFR to 56.6 ± 2.1 ml/min/1.73 m2 in comparison with the initial data (p < 0.05) and the results obtained in group I — 50.8 ± 1.9 ml/min/1.73 m2 (p < 0.05). In group I with traditional stable glucose-lowering and antihypertensive therapy, only 3 patients (9.1 %) transferred from category A2 to category A1 (normoalbuminuria) after 3 months and 2 patients (11.8 %) from category A3 to category A2. In group II, the appointment of Lespedeza capitata (Libera) in combination with stable glucose-lowering and antihypertensive therapy facilitated the transfer of 10 patients (27.8 %) from category A2 to A1 and 7 patients (33.3 %) from category A3 to A2 (p < 0.001). Conclusions. Lespedeza capitata (Libera) in combination with traditional stable glucose-lowering and antihypertensive therapy contributes to the preservation and improvement of the filtration function of the kidneys, a decrease in AER/ACR in patients with CKD stage 2–3 (3a і 3b) against the background of type 2 DM and proves renoprotective efficiency and safety.

scholarly journals Association of aspartate and alanine transaminases with dyslipidemia in newly diagnosed and long duration of type 2 diabetes mellitus subjects.

2021 ◽  
Vol 28 (12) ◽  
pp. 1711-1717
Author(s):  
Nazish Waris ◽  
Samina Bano ◽  
Asher Fawwad ◽  
Abdul Basit
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Group Iv ◽  
Newly Diagnosed ◽  
Group Iii ◽  
Type 2 Dm ◽  
Group I ◽  
Group Ii ◽  
Dm Type 2

Objective: Association between alanine transaminase (ALT) and aspartate transaminase (AST) with newly diagnosed and known type 2 diabetes mellitus (DM) and to estimate association of liver enzymes with lipid profile in type 2 DM subjects. Study Design: Prospective Clinical study. Setting: Karachi University with Collaboration of Baqai Institute of Diabetology and Endocrinology. Period: November 2018 to May 2019. Material & Methods: Total 100 people were divided into four groups; Group I: 25 healthy controls with normal glucose tolerance, Group II: 25 newly diagnosed DM, Group III: 25 known DM type 2 with <5years duration and Group IV: 25 known DM type 2 between 5-10 years duration. Baseline data was collected on predesigned questionnaire. Blood samples for biochemical parameters were analyzed using standardized laboratory techniques. Results: Group I mean age (years) was 50.78±2.34, group II 50.56±1.96, group III 50.37±1.46 and group IV 56±1.36. In Group I, ALT and AST were significantly correlated to each other’s. In group II, ALT was significantly correlated with AST, triglycerides and HDL-C, while AST correlated with ALT and HDL-C. In group III, ALT was significantly correlated with AST, while AST correlated to ALT, triglycerides and HbA1c. However, in group IV, ALT was significantly correlated with AST, LDL-C and HDL-C, and, AST with ALT, total cholesterol, LDL-C and HDL-C. Conclusion: Elevated ALT and AST- the salient markers for disease of non-alcoholic fatty liver with deranged dyslipidemia were found in known type 2 DM as well as in newly diagnosed type 2 DM subjects.

scholarly journals Study of the Osteoporotic Changes in Postmenopausal Women with Type-2 Diabetes Mellitus

2017 ◽  
Vol 18 (1) ◽  
pp. 21-26
Author(s):  
Ayesha Jahan ◽  
Rokeya Begum ◽  
Khaled Bin Shamsuddin
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Femoral Neck ◽  
Postmenopausal Women ◽  
Mineral Density ◽  
Group I ◽  
Group Ii

Introduction: Osteoporosis and Diabetes Mellitus (DM) are common medical conditions in the society with an increasing prevalence in elderly people. Osteoporosis is more common in female than male and postmenopausal women are vulnerable to it.   Objective: The aim of this study was to verify the effect of type-2 diabetes mellitus on bone mineral density in postmenopausal women and, thereby, to evaluate the risk of osteoporosis in them.   Materials and Methods: This cross-sectional study was carried out at National institute of Nuclear Medicine and Allied Sciences (NINMAS), BSMMU campus, Shahbagh, Dhaka, over a period of one year. 175 postmenopausal women were enrolled as study subjects, among them 72 (41.10%) were diabetic and rest 103 (59.90%) were nondiabetic and they were assigned as Group-I and Group-II respectively. The bone mineral density (BMD) was measured by central DEXA device at lumbar spines and left femoral neck of each study subject.   Results: The mean (±SD) ages of group-I and group-II were 58.79 (±8.06) and 58.27 (±8.39) respectively with an age range of 45 to 75 years in both cases. A total of 30 (41.66%) patients in diabetic group (group-I) and 40 (38.83%) patients in non-diabetic (group-II) had osteoporosis at lumbar spines. On the other hand, 40 (56.94%) patients in group-I and 58 (56.31%) patients in group-II had osteoporosis at femoral neck. The Odds Ratios of osteoporosis for lumbar spines and femoral. neck were 1.125 and 1.026 respectively. The differences of frequencies of osteoporosis between group-I and group-II were not statistically significant at any anatomical site and the association between osteoporosis and type-2 diabetes mellitus was not significant. According to Odds Ratio type-2 diabetes mellitus was not a risk factor for developing osteoporosis in postmenopausal women.   Conclusion: Postmenopausal women are prone to develop osteoporosis and type-2 diabetes mellitus may have adverse influence on osteoporosis, which was supported by few previous studies. This study could not establish any significant effect of type-2 diabetes mellitus on osteoporosis in postmenopausal women.Bangladesh J. Nuclear Med. 18(1): 21-26, January 2015

scholarly journals Autoantibody as markers of the heart state in patients with vibration disease burdened diabetes mellitus

2020 ◽  
Vol 22 (2) ◽  
pp. 311-318
Author(s):  
L. B. Masnavieva ◽  
I. V. Kudaeva ◽  
Yu. A. Kuznetsova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Thrombus Formation ◽  
The State ◽  
Myocardial Cells ◽  
Diabetes Group ◽  
Vibration Disease ◽  
Group I ◽  
Group Ii

Physical and chemical factors, obesity, lipid metabolism disorder, diabetes affect the state of the vascular endothelium, the processes of thrombus formation, fibrinolysis and increase the risk of developing cardiovascular diseases. It can be assumed that the development and course of pathological processes in the cardiovascular system, caused by vibration disease with the onset of diabetes, will undergo changes. The purpose of the study was to assess the state of heart condition according to the level of specific autoantibodies with the combined effect of vibration disease and type 2 diabetes mellitus. Patients with vibration disease (group I), patients with type 2 diabetes (group II) and persons with vibration disease in combination with type 2 diabetes (group III) were examined. Individuals do not have a history of coronary heart disease, stroke, and myocardial infarction have been included in obsledrovanie. Serum levels of specific autoantibodies characterizing the state of the heart have been studied. It was revealed that the content of autoantibodies to 1-adrenoreceptors in patients of group I was higher than in individuals of group II. The relative content of autoantibodies to the components of the membrane and cytoplasm of myocardial cells in patients of groups I-III did not differ. It was found that elevated levels of autoantibodies to components of the membrane and cytoplasm of myocardial cells, cardiomyosin, 1-adrenoreceptors were observed more often in patients with vibration disease combined with diabetes and in persons with vibration disease than in people with diabetes. Persons with a reduced content of autoantibodies to 1-adrenergic receptors were not detected among patients of groups I and III. Changes in the levels of specific autoantibodies in persons with vibration disease may indicate the development of functional metabolic and structural changes in the heart, disorders of its electrical activity that have not yet been manifested in the form of a pathological process. Lower levels of 1-adrenoceptor autoantibodies in patients with type 2 diabetes without vibration disease can be caused by increased levels of catecholamines, which is characteristic of diabetics. Further research, including clinical data and indicators of functional diagnostics is necessary to confirm our assumptions.

scholarly journals A COMPARATIVE STUDY OF EFFICACY AND SAFETY AMONG METFORMIN WITH SITAGLIPTIN, METFORMIN WITH VOGLIBOSE, AND METFORMIN WITH GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

2017 ◽  
Vol 10 (12) ◽  
pp. 313
Author(s):  
Kala P ◽  
Jamuna Rani R ◽  
Kumar Js
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Plasma Glucose ◽  
P Value ◽  
Efficacy And Safety ◽  
Group Iii ◽  
Group I ◽  
Group Ii

Objective: Type 2 diabetes mellitus (DM) is a most common metabolic disorder. The present study aimed to compare the efficacy and safety among metformin with sitagliptin, metformin with voglibose, and metformin with glimepiride in patients with type 2 DM. Methods: This study was a prospective, randomized clinical trial study, conducted in patients attending the diabetology outpatient department of SRM Medical College Hospital and Research Center, Potheri, Kancheepuram, Tamil Nadu, from January 2013 to January 2014. The patients were randomized into three groups with 40 patients in each group. Fasting plasma glucose (FPG), 2 hrs postprandial plasma glucose (PPG), and hemoglobin A1c (HbA1c) level were assessed in all the patients before starting the treatment. In Group I, patients were prescribed metformin 500 mg with sitagliptin 50 mg, in Group II, patients were given metformin 500 mg with voglibose 0.2 mg, and in Group III, patients were put on metformin 500 mg with glimepiride 1 mg in the fixed combination. The outcome of the therapy was based on the level of improvement in the blood parameters. Results: There was a significant reduction of FPG level seen in all three groups (p value - Group I <0.0001, Group II < 0.005, and Group III <0.0001). Group I and III showed significant reduction of PPG with p value <0.0001. There was a significant reduction of HbA1c seen in all the three groups (p<0.0001). Conclusion: From the results of this study, it could be concluded that all the three groups were comparable in their efficacy.

scholarly journals Indicators of microcirculation in patients with type 2 diabetes with diabetic peripheral neuropathy during therapy with various doses of vitamin D

2019 ◽  
Vol 18 (4) ◽  
pp. 19-28
Author(s):  
A. P. Stepanova ◽  
T. L. Karonova ◽  
M. M. Galagoudza
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Peripheral Neuropathy ◽  
Diabetic Peripheral Neuropathy ◽  
Functional Tests ◽  
Disability Score ◽  
Doppler Flowmetry ◽  
Group I ◽  
Group Ii

Aim of the study. To study the effect of therapy with prophylactic and supraphysiological doses of cholecalciferol on skin microcirculation (MC) indicators in patients with type 2 diabetes mellitus with diabetic peripheral neuropathy (T2DM with DPN).Material and methods. The study included 62 participants with T2DM with DPN (according to the Neuropathy Disability Score (NDS) scale, more than 4 points). By the method of consecutive numbers, patients were randomized into two groups: Group I (n=31, 15 men/16 women, 52.4±5.7 years) and Group II (n=31, 16 men/15 women, 51.4±6.1 years). Antihyperglycemic treatment was stable during the study. For 24 weeks, cholecalciferol participants from Group I received once a week at a dose of 5,000 IU, and from Group II - once a week at a dose of 40,000 IU. Body mass index (BMI), serum levels of 25(OH)D (25-hydroxycalciferol) and serum glycated hemoglobin (HbA1c) were evaluated before and after 24 weeks of taking cholecalciferol. The method of laser Doppler flowmetry (LDF) compared the initial and final indicators of the baseline level of blood flow and microcirculation indicators against the background of functional tests (postural and occlusive). Control measurements of LDF parameters were performed on 16 subjects without revealed diabetes mellitus (8 men/8 women, 51.8±3.7 years).Results. Patients from Group II, after 24 weeks of taking supraphysiological doses of cholecalciferol, against the background of 100% normalization of the serum 25(OH)D level, significantly improved the parameters of skin MC and functional tests, HbA1c and BMI decreased.Conclusions. Acceptance of high doses of cholecalciferol for 24 weeks has been associated with an improvement in the parameters of glycaemia and indicators of cutaneous MC in patients with T2DM with DPN.

scholarly journals Comparative Effects of Cane Sugar, Honey & Jaggery on Plasma Glucose Level & Body Weight of Alloxan Induced Diabetic Rats

2021 ◽  
Vol 35 (3) ◽  
pp. 44-49
Author(s):  
Ambreen Anjum
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Body Weight ◽  
Cane Sugar ◽  
Serum Glucose ◽  
Distilled Water ◽  
Group I ◽  
Body Weights ◽  
Group Ii

Introduction: Diabetes mellitus is characterized by hyperglycemia with impaired metabolism of carbohydrates, fats, and proteins resulting from insufficiency of secretion or action of insulin. The interplay of genes and environmental factors is believed to stress glucose homeostasis. Simple dietary and lifestyle modifications have a role in prevention and slow progression of the disease. The choice and role of sweeteners (sugars) such as ordinary cane sugar, honey, and jaggery have always been a difficult decision for patients with Type 2 diabetes. Aims & Objectives: Evaluation and comparison of the effects of cane sugar, honey, and jaggery on plasma glucose in the sera and body weights of alloxan-induced male Wistar rats with diabetes. Place and duration of study: The study was conducted at the animal house of Services Institute of Medical Sciences Lahore for a duration of 20 months approximately. Material & Methods: In this experimental study 120 male Wistar (albino) rats were randomly allocated into 4 groups of 30 each. After acclimatization, freshly prepared 2% alloxan monohydrate was administered to all the rats via intraperitoneal injection in a single dose of 120mg/kg body weight. Blood sample via tail tipping method was analyzed for fasting serum glucose at 4th post-diabetes induction day. Rodents having ? 200mg/dl serum glucose were regarded as type 2 diabetes models for further study. All animals had access to usual pelleted diet ad libitum. Diabetic controls in group I were fed with equivalent amount of distilled water. Group II, III and IV rats were fed freshly prepared sweetener containing cane sugar, honey and jaggery solutions respectively in a dose of 1g/kg body weight dissolved in 2ml distilled water on pre-scheduled time of the day for 28 days via oral syringe-dosing. Final serum glucose was estimated at 29th day of study by terminal blood sampling and final body weights were recorded. Data analysis was performed using SPSS version 20. Results: Group III (honey fed) rats had least hyperglycemia of 34.53±77.31mg/dL, followed by group II (cane sugar fed) rats (79.31±73.03 mg/dL) then group I diabetic control rats (88.11±92.56mg/dL) and maximal rise in jaggery fed rats with value of 134.50 mg/dL. Significant reduction (p=0.049) in body weight (-40.50g) was noted in group II rats whereas maximum weight gain occurred in group I (127.57 ±72.475), than those of group IV rats (69.13 ± 92.88) followed by II rats (38.42±89.43). Conclusion: The result demonstrates that honey in type 2 diabetes mellitus possess antidiabetic properties via minimum hyperglycemic and weight gaining effects than processed cane sugar. As it was presumed, minimally processed jaggery has not shown significant beneficial effects on serum glucose and body weight. Owing to the advantageous effects on metabolic profile, honey may be regarded as a relatively safer sweetener in diabetics.

scholarly journals Evaluation of Salivary Procalcitonin and Macrophage Activating Factor in Generalised Chronic Periodontitis Patients with and without Type 2 Diabetes Mellitus

2021 ◽  
Author(s):  
Sindhu Ramarao Ghorpade ◽  
Vijayalakshmi Rajaram ◽  
Jaideep Mahendra ◽  
Burnice Nalinakumari Chelladurai ◽  
Ambalavanan Namasivayam
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Chronic Periodontitis ◽  
P Value ◽  
Group I ◽  
Significant Difference ◽  
The Mean ◽  
Group Ii

Introduction: Periodontitis is a polymicrobial and multifactorial oral disease and is the sixth complication of diabetes mellitus. Early diagnosis is important, and the use of non invasive biomarkers are highly useful for this purpose. The level of Macrophage Activating Factor (MAF) and Procalcitonin (ProCT) corresponds to the intensity of the inflammatory response and the severity of infection; thereby indicating that an increase in concentration or persistence of high values is considered as a prognostic indicator for severity of infection with an adverse outcome. Aim: To assess the periodontal parameters and quantify the levels of MAF and ProCT in saliva samples of generalised chronic periodontitis subjects with and without type 2 diabetes mellitus and to correlate these levels with the periodontal parameters. Materials and Methods: The study was a single centre cross- sectional study carried out at the Department of Periodontology, Meenakshi Ammal Dental College and Hospital, Chennai, Tamil Nadu, India, from November 2018 to November 2019. A total of 80 subjects with generalised severe chronic periodontitis were selected and divided into two groups. Group I comprised of 40 subjects who were diagnosed with generalised chronic periodontitis without type 2 diabetes mellitus, whereas group II comprised of 40 subjects with generalised chronic periodontitis who had already been diagnosed with type 2 diabetes mellitus. Periodontal parameters such as Plaque Index (PI), Bleeding on Probing (BOP), Probing Pocket Depth (PPD) and Clinical Attachment Level (CAL) were recorded. The collected samples were subjected to molecular analysis for evaluating ProCT and MAF using Enzyme-Linked Immunosorbent assay (ELISA). Statistical analysis was done using Statistical Package for Social Sciences (SPSS) version 25.1 (Chicago, USA Inc). Student’s Independent t-test was used to compare the mean values for the variables in the control and test group. The Pearson’s correlation test was used to evaluate correlation between all the variables. The p-value <0.05 was set as the level of significance. Results: On comparing the periodontal parameters between group I and group II, there was no significant difference between the groups p-value >0.05. The mean salivary ProCT level in group I and group II was 268.76±152.78 ng/mL and 785.75±244.37 ng/mL, respectively. The mean salivary MAF level in group I and group II was 7.15±2.02 ng/mL and 26.56±9.12 ng/mL, respectively. On comparing MAF and ProCT value between group I and group II, there was a statistically significant increase in group II (p-value <0.001) and a weak correlation value with the periodontal parameters was seen. Conclusion: There was a significant difference in levels of MAF and ProCT in saliva samples of generalised chronic periodontitis subjects with and without type 2 diabetes mellitus, however the periodontal variables in each group did not correlate with MAF and ProCT.

scholarly journals Choice of optimal antihypertensive therapy in patients with diabetes mellitus type 2

2022 ◽  
Vol 7 (4) ◽  
pp. 62-69
Author(s):  
V. A. Tsvetkov ◽  
E. S. Krutikov ◽  
S. I. Chistyakova
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Heart Rate ◽  
Heart Rate Variability ◽  
Arterial Hypertension ◽  
Antihypertensive Therapy ◽  
Target Blood Pressure ◽  
Group I

Aim of the study: to develop personalized approaches to combined antihypertensive therapy in patients with type 2 diabetes mellitus and arterial hypertension, depending on the parameters of the daily blood pressure profile and heart rate variability.Material and methods. We examined 322 patients with type 2 diabetes and arterial hypertension who had not previously received antihypertensive drugs on a regular basis. At the first stage, patients were prescribed Perindopril 10 mg per day and Indapamide retard 1,5 mg per day. In the absence of reaching target blood pressure (BP) levels after 28 days, a third antihypertensive drug was added — Amlodipine 5 mg per day, followed by titration to 10 mg 1 r per day (group I) or a b-blocker — Carvedilol at a dose of 12,5 mg 2 r per day, also followed by titration up to 25 mg 2 r per day (group II). Daily monitoring of BP and ECG was carried out, the average daily heart rate (HR), circadian index (CI), as well as heart rate variability were determined.Results and its discussion. Patients with type 2 diabetes have a high variability of blood pressure throughout the day, high pulse blood pressure, as well as a rigid circadian profile of heart rate. The appointment of a standard two-component antihypertensive therapy, including Perindopril 10 mg and Indapamide retard 1,5 mg per day, allows reaching the target blood pressure only in 46% of patients. The addition of amlodipine or carvedilol significantly increases the effectiveness of therapy, allowing more than 80% of patients to achieve the target blood pressure. At the same time, the use of amlodipine leads to a greater extent to a decrease in pulse pressure, and the inclusion of carvedilol improves the circadian profile of blood pressure and heart rate, and has a positive effect on heart rate variability.

scholarly journals Comparison of glucose lowering ability of Pioglitazone and Glimepiride in Steptozotocin induced type 2 diabetes mellitus male mice model

2021 ◽  
Vol 15 (6) ◽  
pp. 2156-2158
Author(s):  
Hina Aslam ◽  
Saima Rafique ◽  
Sidra Mumal ◽  
Furqan Ali Shah ◽  
Abeerah Zainub ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Control Group ◽  
Male Mice ◽  
Mice Model ◽  
Group I ◽  
Group Ii ◽  
Hba1c Levels

Introduction: Diabetes mellitus type 2 is a global health problem expanding at an alarming rate and putting individuals at high risk of microvascular and macrovascular complications. Life style modification and drugs intervention can help achieve normal glucose levels. Aim &Objective: To compare the hypoglycemic activity of glimepiride and pioglitazone in a type 2 diabetes mellitus induced male mice model. Place & Duration of study: This study was carried out in the animal house of National Institute of Health (NIH), Islamabad from 7th November 2013 till 21st January 2014. Materials & Methods: Forty albino Balb/C male mice were divided randomly into groups I-IV (n=10). Group I served as normal control group. In rest of mice from group II-IV, type 2 diabetes mellitus was induced by administration of high fat diet (HFD) for two weeks followed by low dose (40 mg/kg) intra-peritoneal streptozotocin (STZ) injections for four consecutive days. Group II served as the disease control group. Group III received Glimepiride in a dose of 2mg/kg body wt. while group IV was administered Pioglitazone in a dose of 30mg/kg body wt. Both the drugs were given orally once a day. Samples were taken at the end of ten weeks. Results: The blood samples estimated for fasting blood glucose (FBG) & glycosylated hemoglobin (HbA1c %) levels showed that both glimepiride and pioglitazone equally lowered the FBG and HbA1c% levels. However, pioglitazone lowered the FBG and HbA1c levels slightly more than Glimepride. Conclusion: Glimepiride and pioglitazone lowered the FBG and HbA1c levels in type 2 diabetes induced male mice with the later having slightly more reduction than Glimepride. Key words: Glimepiride, Pioglitazone, Streptozotocin, type 2 Diabetes Mellitus.

scholarly journals The influence of type 2 diabetes mellitus on salivary matrix metalloproteinase-8 levels and periodontal parameters: A study in an Indian population

2015 ◽  
Vol 09 (03) ◽  
pp. 319-323 ◽  
Author(s):  
Namita Gupta ◽  
Narinder Dev Gupta ◽  
Akash Gupta ◽  
Lata Goyal ◽  
Sagar Garg
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Matrix Metalloproteinase ◽  
Periodontal Disease ◽  
Chronic Periodontitis ◽  
Group Iii ◽  
Type 2 Dm ◽  
Group I

ABSTRACT Objective: Although many studies reported more severe periodontal disease and the existing proinflammatory conditions in patients with diabetes but only few have examined the effect of type 2 diabetes mellitus (DM) on salivary matrix metalloproteinase-8 (MMP-8) level and other periodontal parameters. This study aims to evaluate the effect of type 2 DM on salivary MMP-8 levels and periodontal parameters, which might be useful in monitoring periodontal disease in diabetes. Materials and Methods: A total of 90 subjects were selected for the study and were divided into three groups: Group I included 30 healthy subjects; Group II included 30 subjects without type 2 DM but with chronic periodontitis, and Group III included 30 subjects with type 2 DM and chronic periodontitis. Periodontal parameters such as plaque index (PI), gingival index (GI), pocket probing depth (PPD), and clinical attachment level (CAL) were taken. The salivary MMP-8 level was estimated by Quantikine Human total MMP-8 immunoassay kit using ELISA method. Results: The mean value of the salivary MMP-8 of Group III was highest followed by Group II and Group I, the least. The other periodontal parameters PI, GI, PPD, CAL, was comparatively highest for Group III. Conclusion: This study suggests that diabetes is associated with an increased prevalence, extent, and severity of periodontitis. Furthermore, the increased levels of MMP-8 indicate the influence of diabetes on their salivary concentration.

Sign in / Sign up

Export Citation Format

Share Document